We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis
Product News

Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis

Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis
Product News

Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Protagen AG has today launched its first ELISA research use test kit for Systemic Sclerosis (SSc), the ADx®SSc Multilisa®. Protagen developed the new assay to synergistically combine two proprietary, novel disease markers with two standard diagnostic markers to support medical research in autoimmune diseases.
Stefan Müllner, CEO of Protagen AG, said: “Based on our long track record in the discovery and validation of autoantigen biomarkers using the proprietary SeroTag® technology, our development pipeline is built on a strong patent portfolio and designed to support clinical research, targeted therapy, and the continuous delivery of novel diagnostic products.”
 
Systemic sclerosis is one of a number of complex autoimmune diseases that Protagen is working to address with research tools to help clinical researchers in their work to identify markers for improved diagnostics. This new introduction represents a key milestone in the company’s pipeline. Müllner added, “This underscores our strategy to provide new, improved solutions and product options in autoimmune indications on a continuous basis, enable better therapeutic decision making and improve the diagnostic process for clinicians and, importantly, patients.”
 
ADx®SSc Multilisa® is intended for use as a scientific research-use only (RUO) product, and is in further clinical testing to build a diagnostic claim for early disease detection or stratification from August 2014.

Advertisement